Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...
By Mrinalika Roy and Bhanvi Satija (Reuters) -As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback